| Ibrutinib maintenance |
BTK Inhibitor |
MCL |
36 |
2 |
NCT02242097 |
2014 |
Recruiting |
| Lenalidomide maintenance versus observation |
immuno-modulatory agent |
Advanced MCL |
300 |
3 |
NCT02354313 |
2014 |
Recruiting |
| ACP-196 |
BTK Inhibitor |
relapsed or refractory MCL |
Recruiting/estimated number:120 |
2 |
N+F2:I15CT02213926 |
2014 |
Recruiting |
| Bendamustine, Rituximab, Ibrutinib |
Alkylating agent + monoconal Ab + BTK Inhibitor |
Newly Diagnosed MCL |
520 |
3 |
NCT01776840 |
2013 |
Active, not recruiting |
| GS-9973 |
Spleen tyrosine kinase (SYK) inhibitor |
Relapsed/Refractory MCL, CLL, DLBCL & iNHL |
280 |
2 |
NCT01799889 |
2013 |
Recruiting |
| GS-9973 + Idelalisib |
Spleen tyrosine kinase (SYK) inhibitor & PI3Kδ inhibitor |
Relapsed or Refractory Hematologic Malignancies (MCL,CLL, FL, DLBCL and iNHL) |
200 |
2 |
NCT01796470 |
2013 |
Active, not recruiting |
| SGN-CD19A |
anti-CD19 mAb linked to monomethyl auristatin F (MMAF), a cytotoxic agent |
MCL |
120 |
1 |
NCT01786135 |
2013 |
Recruiting |
| Ublituximab+Ibrutinib |
Anti-CD20 monoclonal antibody+Bruton's Tyrosine Kinase (BTK) inhibitor |
MCL,Chronic Lymphocytic Leukemia |
60 |
2 |
NCT02013128 |
2013 |
Enrolling by invitation |
| AT7519M |
CDK Inhibitor |
Relapsed MCL |
12 |
2 |
NCT01652144 |
2012 |
Completed; results are awaited |
| Carfilzomib, Lenalidomide, Rituximab |
proteasome inhibitor + immuno-modulatory agent + monclonal Ab |
Relapsed/Refractory MCL |
68 |
1&2 |
NCT01729104 |
2012 |
Recruiting |
| IMMU-114 |
Humanized mAb against HLA-DR |
Relapsed or Refractory NHL and CLL |
50 |
1 |
NCT01728207 |
2012 |
Recruiting |
| CEP-9722 + Gemcitabine + Cisplatin |
PARP inhibitor + antimetabolite deoxynucleoside analogue + inorganic platinum agent |
MCL |
24 |
1 |
NCT01345357 |
2011 |
Completed; results are awaited |
| CC-122 HCL |
Pleiotropic Pathway Modulator |
MCL |
140 |
1 |
NCT01421524 |
2011 |
Recruiting |
| CDX-1127 (Varlilumab) |
Monoclonal antibody targeting CD27 |
refractory or relapsed CD27 Expressing B-cell Malignancies and selected types of solid tumors |
170 |
1 |
NCT01460134 |
2011 |
Recruiting |
| Ofatumumab + Bendamustine |
Alkylating agent & CD20 antibody |
MCL Ineligible for Autologous Stem Cell Transplant |
76 |
2 |
NCT01437709 |
2011 |
Recruiting |
| Panobinostat + Bortezomib |
histone deacetylase inhibitor (HDAC inhibitor) &Proteasome inhibitor |
Relapsed and/or Refractory MCL |
24 |
1 |
NCT01504776 |
2011 |
Completed; results are awaited |
| R-CHOP-14R-HIDAC followed by RIT/HDT/ASCR |
Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation |
Untreated Advanced Stage MCL |
96 |
1&2 |
NCT01484093 |
2011 |
Active, not recruiting |
| SAR245409+Rtuximab + Bendamustine |
Phosphoinositide 3-kinase inhibitor (PI3K inhibitor)+monoclonal Ab+alkylating gent |
Relapsed or Refractory MCL & other kinds of lymphoma |
85 |
2 |
NCT01403636 |
2011 |
Completed; results are awaited |
| SNS01-T |
Small inhibitory RNA molecule that blocks the expression of Factor 5A mRNA |
MCL in Relapse and other B cell malignancies |
15 |
1&2 |
NCT01435720 |
2011 |
Active, not recruiting |
| PD 0332991 + Bortezomib |
Cyclin-dependent kinase 4 and 6 inhibitor & Proteasome inhibitor |
Relapsed MCL |
30 |
1 |
NCT01111188 |
2010 |
Unknown |
| Bendamustine + rituximab versus CHOP + rituximab |
B: mechlorethamine R:monoconal Ab RCHOP:Chemoimmunotherapy |
first-line treatment for patients with stage III or IV indolent or MCL |
549 |
3 |
NCT00991211 |
2009 |
Completed; results are awaited |
| Tositumomab and Iodine I 131 Tositumomab followed by CHOP |
iodine-131 labeled anti-CD20 murine IgG2a monoclonal antibody + chemotherapy |
untreated MCL |
25 |
2 |
NCT00992992 |
2009 |
Completed; results are awaited |
| Rituximab as maintenance |
CD20 antibody |
MCL |
299 |
3 |
NCT00921414 |
2009 |
Completed; results are awaited |
| Vorinostat |
histone deacetylase (HDAC) inhibitor |
MCL and other B cell NHL |
54 |
2 |
NCT00875056 |
2009 |
Active, not recruiting |
| Bortezomib as maintenance |
Proteasome inhibitor |
untreated MCL |
151 |
2 |
NCT00310037 |
2008 |
Active, not recruiting |
| Clofarabine |
Nucleoside analogue |
Relapsed/Refractory NHL |
25 |
1&2 |
NCT00644189 |
2008 |
Completed; results are awaited |
| Epratuzumab or rituximab |
anti-CD22 + anti-CD20 monoclonal antibody |
NHL patients receiving antibody treatment |
500 |
Not available |
NCT00398372 |
2006 |
Completed; results are awaited |
| RT-PEPC (Rituximab, Thalidomide, Prednisone, Etoposide, Procarbazine, Cyclophosphamide) |
Monoclonal antibody, immunomodulatory, immunosuppressant drug, Topoisomerase inhibitor, alkylating agent |
Relapsed Mantle Cell Lymphoma |
46 |
2 |
NCT00151281 |
2005 |
Unknown |
| Cladribine |
Antimetabolite |
Mantle Cell Lymphoma |
48 |
2 |
NCT00002879 |
1999 |
Completed; results are awaited |
